Helus Pharma Phase 3 MDD trial surpasses 86% enrollment
Tweet Send to a Friend
Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) announced that enrollment in its APPROACH Phase 3 clinical trial of HLP003 for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


